A case is reported of an adult who presented with hyperkalaemic muscular paralysis induced by spironolactone.
Introduction
Hypokalaemic muscular weakness is well known (Ward, 1978; Bannister, Ginsbury and Shneerson, 1977) but paralysis due to hyperkalaemia has rarely been described (Hoskins, Vroom and Jarrell, 1975 ; Van der Meulen, Gilbert and Kane, 1961) . The majority of cases are hereditary and episodic (Tyler et al., 1951; Helweg-Larsen, Hauge and Sagild, 1955 (Editorial, 1978) . Its use as a lone diuretic is not well documented but even as adjunct therapy its use is fraught with danger in poorly selected cases (Greenblatt and Koch-Weser, 1973; Herman and Rado, 1966) . Hyperkalaemia is the commonest and most serious side effect, being occasionally associated with sudden death most probably due to arrhythmia (Herman and Rado, 1966) . This risk is particularly high in patients with impaired renal function and in those receiving potassium supplements. This should be more so when spironolactone is used alone. Biochemical control is vital in all such cases. Hyponatraemia, dehydration, gastrointestinal, and neurological disturbance including weakness, drowsiness and confusion are other common side effects. Skin rashes and gynaecomastia occur but are not common.
It is interesting that this patient had no cardiac arrhythmia despite a very high level of serum potassium, especially as he also had hyponatraemia which augments hyperkalaemic effects on the muscle membrane (Klein, Egan and Usher, 1960) . However, although arrhythmias may be associated with profound and rapid changes in the serum potassium concentration, there is a poor correlation between the serum potassium concentration and the incidence of arrhythmias (Taggart and Slater, 1971) . Other factors which affect this include myocardial catecholamine action, temperature, glucose metabolism, variations in the electrophysiological characteristics of different cell types and the potassium gradient across the myocardial cell membrane (Taggart and Slater, 1971) . Hyperkalaemia can occur within one week of starting spironolactone (Greenblatt and Koch-Weser, 1973 ) although the diuretic effect may not become optimal until after about 5 days. It may be that the prolonged period of therapy in this case was associated with increased body potassium as well as hyperkalaemia, thus causing a change in the potassium gradient across the myocardial cell membrane, towards normal. This can only be speculative however as total body potassium was not measured. The high WBC and ESR were probably due to the acute illness; old age was probably also a contributory factor to the high ESR. Uraemia and hyponatraemia are well recognized features of diuretic treatment (Davies and Wilson, 1975) . The dramatic response to insulin and glucose, with complete recovery after correction of the hyperkalaemia, ruled out the possibility of the Guillain-Barre syndrome.
Biochemical control is important in diuretic therapy especially, as illustrated in this report, when spironolactone is used. 
